In this video, Eric Schlorff, CEO of SeaStar Medical, discusses how the company is using its FDA Breakthrough Device designation to improve care for critically ill patients suffering from hyperinflammation. SeaStar's innovative therapy, QUELIMMUNE, treats pediatric acute kidney injury caused by sepsis. The company is also conducting trials on a second device targeting adult acute kidney injury, with a market potential of over 4.5 billion dollars. Their advancements aim to save lives and tackle serious health conditions more effectively.